Log In
Print
BCIQ
Print
Print this Print this
 

Cyramza, ramucirumab (IMC-1121B, LY3009806)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionHuman IgG1 mAb VEGFR-2 antagonist
Molecular Target Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2)
Mechanism of ActionVascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) antagonist; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today